Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amylyx

Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP).

Benzinga

Steve Cohen's Point72 Goes Heavy on Tech and Pharma Stocks, Investing Over $330M in Two Trades

Point72 Asset Management recently purchased over 10 million shares of Confluent and Amylyx Pharma common stock, worth more than $334.17 million.

International Business Times UK

Lots of drug companies talk about putting patients first — but this one actually did

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure

Amylyx stock crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in its pivotal study.

Investors Business Daily

Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter

Sales of Amylyx's ALS drug, Relyvrio, beat fourth-quarter expectations on Thursday, and AMLX stock bounded well above its 50-day line.

Investors Business Daily

Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024

Amylyx missed Wall Street's expectations on Thursday amid struggles for its amyotrophic lateral sclerosis drug, and AMLX stock crashed.

Investors Business Daily

Amylyx Unexpectedly Hits Breakeven With Breakneck Speed — But Shares Dip

Amylyx Pharmaceuticals hit breakeven in its second quarter with a product on the market, an analyst noted Friday. But AMLX stock dipped.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock briefly above its 50-day line Tuesday.

Investors Business Daily

ALS patients contend with $158K price tag on new drug

For two years, Becky Mourey pushed the Food and Drug Administration to approve an experimental drug for her Lou Gehrig’s disease

The Independent UK

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Investors Business Daily

Ice bucket challenge helps to fund FDA-approved motor neurone medication

Millions of dollars raised during the ice bucket challenge craze of 2014 have been used in the development of a new FDA-approved treatment.

The New Daily

ALS drug's approval draws cheers from patients, questions from skeptics

A controversial new drug for ALS could add months to patients' lives – if it actually works

WEKU

Highly Rated Amylyx Pharma Skids After Hard-Fought FDA Approval For ALS Drug

The Food and Drug Administration granted Amylyx Pharmaceuticals a hard-won approval in ALS treatment, but AMLX stock sank Friday.

Investors Business Daily

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Boston Herald

‘If not for the Ice Bucket Challenge, we wouldn’t be here’: Cambridge company on the brink of FDA-approved ALS treatment

BOSTON — Eight years after the ALS Ice Bucket Challenge went viral across social media and raised hundreds of millions of dollars for research, a Cambridge company is on the brink of a major breakthrough for ALS patients.

The Independent UK

ALS drug gets rare second review at high-stakes FDA meeting

The Food and Drug Administration is holding an unusual second meeting to review a closely watched drug for the illness known as Lou Gehrig’s disease

Investors Business Daily

The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff

The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological treatment, and shares crashed.

The Independent UK

FDA still skeptical of ALS drug ahead of high-stakes meeting

The U.S. Food and Drug Administration has posted another negative review of a closely watched drug for the deadly neurodegenerative disease ALS

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Investors Business Daily

Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again

IPO stock Amylyx Pharmaceuticals jumped Monday as the Food and Drug Administration prepares to review its controversial ALS treatment again.

Benzinga

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

Benzinga

Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September

The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.

Investors Business Daily

Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug

The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed.

Benzinga

Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.

Investors Business Daily

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest

U.S. officials will soon examine Reata's request to treat a neurodegenerative condition, and RETA stock continued its two-day climb Friday.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Amylyx Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.